Thyrocare Technologies Limited Reports Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2016
January 28, 2017 at 10:39 am
Share
Thyrocare Technologies Limited reported unaudited standalone and consolidated earnings results for third quarter and nine months ended December 31, 2016. For the quarter, the company reported standalone net sales/income from operations of INR 673.66 million, profit from operations before other income and finance costs and exceptional items of INR 237.71 million, profit from ordinary activities before tax of INR 261.01 million, net profit of INR 169.0 million or INR 3.14 per diluted share, compared to the net sales/income from operations of INR 538.08 million, profit from operations before other income and finance costs and exceptional items of INR 197.02 million, profit from ordinary activities before tax of INR 207.22 million, net profit of INR 130.91 million or INR 2.58 per diluted share, for the same quarter a year ago.
For the year to date, the company reported standalone net sales/income from operations of INR 2,096.23 million, profit from operations before other income and finance costs and exceptional items of INR 751.59 million, profit from ordinary activities before tax of INR 830.94 million, net profit of INR 545.39 million or INR 10.14 per diluted share, compared to the net sales/income from operations of INR 1,639.95 million, profit from operations before other income and finance costs and exceptional items of INR 612.83 million, profit from ordinary activities before tax of INR 654.15 million, net profit of INR 433.01 million or INR 8.53 per diluted share, for the same period a year ago.
For the quarter, the company reported consolidated net sales/income from operations of INR 682.64 million, profit from operations before other income and finance costs and exceptional items of INR 220.92 million, profit from ordinary activities before tax of INR 245.8 million, net profit of INR 153.79 million or INR 2.86 per diluted share, compared to the net sales/income from operations of INR 540.15 million, profit from operations before other income and finance costs and exceptional items of INR 174.54 million, profit from ordinary activities before tax of INR 184.45 million, net profit of INR 108.14 million or INR 2.13 per diluted share, for the same quarter a year ago.
For the year to date, the company reported consolidated net sales/income from operations of INR 2,113.35 million, profit from operations before other income and finance costs and exceptional items of INR 713.86 million, profit from ordinary activities before tax of INR 805.66 million, net profit of INR 520.13 million or INR 9.67 per diluted share, compared to the net sales/income from operations of INR 1,690.34 million, profit from operations before other income and finance costs and exceptional items of INR 552.64 million, profit from ordinary activities before tax of INR 599.81 million, net profit of INR 378.67 million or INR 7.46 per diluted share, for the same period a year ago.
Thyrocare Technologies Limited is an India-based healthcare services provider in diagnostic area. The Company has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The Company's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The Company has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
Thyrocare Technologies Limited Reports Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2016